Interleukin-10 (IL-10) and DNA repair gene PRKDC mutations are implicated in the development of multiple human cancers, including glioma. We investigated associations between IL-10 and PRKDC gene polymorphisms and prognosis in lowand high-grade glioma patients. We analyzed the associations of one IL-10 and one PRKDC single nucleotide polymorphism with patient clinical factors in 481 glioma patients using Cox proportional hazard models and Kaplan-Meier curves. We also assessed associations between patient clinical characteristics and prognosis. Our data showed that the extent of tumor resection (gross-total resection) and application of chemotherapy were associated with improved patient outcomes in all glioma cases. Additionally, univariate (Log-rank p = 0.019) and multivariate Cox regression analyses (p = 0.022) showed that the IL-10 rs1800871 C/T genotype correlates with improved overall survival in cases of low-grade glioma, whereas the PRKDC rs7003908 C/C genotype correlated with reduced overall and progression-free survival in high-grade glioma patients in univariate (Log-rank p = 0.000 and p = 0.000, respectively) and multivariate Cox regression analyses (p = 0.001; p = 0.002, respectively). These results suggest that IL-10 rs1800871 and PRKDC rs7003908 may be useful biomarkers for predicting glioma patient outcome. Further functional studies are needed to evaluate the mechanisms by which these polymorphisms affect glioma progression.
INTRODUCTION
Glioma is a general term used to describe any tumor that arises from the supportive (gluey) tissue of the brain. This tissue, called glia, helps to keep the neurons in place and functioning well. It is the most common and aggressive primary brain tumors, occurring most commonly in adults and accounting for 40-50% of all brain tumors [1] . According to the 2007 World Health Organization (WHO) classification, gliomas are subclassified into four grades based on degree of aggressiveness: grade I (pilocytic astrocytomas), grade II (diffuse infiltrating lowgrade gliomas), grade III (anaplastic gliomas), and grade IV (glioblastomas multiforme) [2] . Low-grade gliomas (grade I-II) are well differentiated, and generally have better prognoses than high-grade gliomas (grade III-IV) [2, 3] . Despite total or near-total tumor resection, and advancements in chemo-radiotherapy, patient outcomes remain dismal. Median survival times for patients with grade III and IV gliomas are only 39 and 30 weeks, respectively [4] .
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Several clinical factors, such as surgical method, radiotherapy, chemotherapy, patient age and gender, and tumor grade, size, range and location, can affect glioma patient prognosis. Most gliomas result from the combined action of environmental factors and inherited genetic variations [5] . Haque, et al. [6] suggested that glioblastoma arises from genetic and epigenetic alterations in normal astroglial cells, implying that genetic factors are primarily responsible for gliomagenesis.
Interleukin-10 (IL-10), an important antiinflammatory cytokine, is secreted by various immune cells. IL-10 has pleiotropic effects on immunoregulation and inflammation, and can promote carcinogenesis [7] . Huettner, et al. [8] suggested that IL-10 promotes glioma progression by enhancing tumor cell invasion and providing an immunosuppressive environment. Additionally, IL-10 polymorphisms are associated with glioblastoma [9] .
PRKDC, also known as human X-ray repair cross-complementing group 7 (XRCC7), is located on chromosome 8q11. Several studies have associated PRKDC with poor prognosis in numerous tumor types, such as esophageal cancer [10] , B-cell chronic lymphocytic leukemias [11] , and colorectal cancer [12] . PRKDC gene polymorphisms are also correlated with glioma risk [13, 14] .
Although previous association studies linked IL-10 and PRKDC genetic polymorphisms with glioma risk, few focused on the effects of these alterations on glioma patient prognosis. In the present study, we selected one single nucleotide polymorphism (SNP) in IL-10 [9] and one in PRKDC [14] , each of which was reportedly associated with glioma risk. We evaluated the associations between these two SNPs and low-and high-grade glioma patient prognosis in a Chinese population. 
RESULTS

Patient clinical data
Univariate analysis
In a univariate analysis of clinical factors, including patient gender and age, extent of tumor resection, and radiotherapy and chemotherapy regimen, we found that the median overall survival (OS) of WHO grade I-II glioma patients (12 months; 3-year survival rate = 9.0%) was longer than that of WHO grade III-IV patients (10 months; 3-year survival rate = 5.5%) (Log-rank p = 0.039) ( Tables 2-4 ). The extent of resection (gross-total resection) was a protective factor, as was chemotherapy, in all glioma patients. Overall, gross-total resection was associated with a 33.3 (Log-rank p = 0.000, HR = 0.667, 95% CI = 0.545-0.817, p = 0.000) and 36.5% (Log-rank p = 0.000, HR = 0.63.5, 95% CI = 0.519-0.777, p = 0.000) decrease in OS and PFS mortality hazards, respectively. Median OS and PFS were 11 and 8 months, respectively, with 10.2% and 6.0% 3-year survival rates. In low-grade glioma patients, gross-total resection was associated with a 32.3% (Log-rank p = 0.000, HR = 0.677, 95% CI = 0.522-0.878, p = 0.003) and 35.8% (Log-rank p = 0.000, HR = 64.2, 95% CI = 0.496-0.831, p = 0.001) decrease in OS and PFS mortality hazards, respectively. Median OS and PFS were 11 and 8 months, respectively, with 12.5% and 7.1% 3-year survival rates. Finaly, in highgrade glioma patients, gross-total resection was associated with a 37.6% (Log-rank p = 0.002, HR = 0.62.4, 95% CI = 0.451-0.864, p = 0.004) and 39.3% (Log-rank p = 0.001, HR = 60.7, 95% CI = 0.439-0.840, p = 0.003) decrease in OS and PFS mortality hazard, respectively. Median OS and PFS were 10 and 8 months, respectively, with 6.9% and 4.5% 3-year survival rates. Treatment with chemotherapy was also associated with an overall reduced risk of death as measured by increased patient OS (3-year survival rate = 14.2%, median survival = 12 months, Log-rank p = 0.000, HR = 0.643, 95% CI = 0.528-0.782, p = 0.000) and PFS (3-years survival rate = 11.6%, median survival = 8 months, Log-rank p = 0.000, HR = 0.731, 95% CI = 0.602-0.889, p = 0.002). This same trend was observed in OS (3-year survival rate = 16.2%, median survival = 12 months, Log-rank p = 0.000, HR = 0.665, 95% CI = 0.517-0.855, p = 0.001) and PFS (3-year survival rate = 13.3%, median survival = 8 months, Logrank p = 0.004, HR = 0.722, 95% CI = 0.523-0.926, p = 0.010) of low-grade glioma patients, and in OS (3-year survival rate = 11.3%, median survival = 12 months, Log-rank p = 0.001, HR = 0.617, 95% CI = 0.450-0.846, p = 0.003) of high-grade patients. No significant correlations were identified between patient gender and age, WHO tumor grade, or radiotherapy and prognosis as measured by OS and PFS.
According to Log-rank tests and Cox regression analysis, the two SNPs we studied were not correlated with OS or PFS in glioma patients (Table 5 ). However, we found that the IL-10 rs1800871 C/T genotype was associated with increased OS in low-grade glioma cases (3-year survival rate = 13.1%, median survival = 12 months, Log-rank p = 0.019, HR=0.745, 95% CI=0.573-0.969, p = 0.028), but not high-grade cases. We also found that the PRKDC rs7003908 C/C genotype correlated with poor prognosis in high-grade glioma patients as measured by OS (3-year survival rate = 0.0%, median survival = 6 months, Log-rank p = 0.000, HR = 4.556, 95% CI = 1.936-10.721, p = 0.001) and PFS (3-year survival rate = 0.0%, median survival = 4 months, Log-rank p = 0.000, HR = 4.430, 95% CI = 1.884-10.416, p = 0.001), although this was not observed in low-grade glioma patients.
Multivariate analysis
Multivariate Cox regression analysis demonstrated that SNP genotype was an independent prognostic factor for OS and PFS after adjustment for the various clinical factors. In the present study, we identified correlations between rs1800871, rs7003908 and prognosis in different glioma grades (Table 6 
DISCUSSION
Gliomas are the most common primary tumors of the central nervous system and several patient prognosis predictors have been identified, including patient age, WHO tumor grade, extent of tumor resection, and radiotherapy and chemotherapy regimen(s) [15] . Consistent with previous studies [16, 17] , we found that chemotherapy and the extent of resection were key prognostic factors in glioma patients. Prognoses differed between low-grade and high-grade glioma patients. After WHO grade stratification, we found that rs1800871 in IL-10 correlated with increased OS in low-grade glioma cases, while rs7003908 in PRKDC correlated with poor prognosis in high-grade cases.
Ours was the first study to associate the IL-10 rs1800871 C/T genotype with improved survival in lowgrade glioma patients. IL-10 gene polymorphisms have been associated with multiple cancers, such as gastric [18] , breast [19] , and non-small cell lung cancer [20] , as well as gliomas [9, 21] . Inflammation plays roles in all phases of tumor development, and IL-10, a well-known immuno-modulatory cytokine, may provide a functional link between inflammation and cancer [22] . AcunerOzbabacan, et al. [22] found that IL-10 deficiency allowed for pro-inflammatory cytokine induction and hindered anti-tumor immunity, thereby promoting tumor growth. Tanikawa, et al. [23] observed that high serum IL-10 levels enhanced the tumor-specific immune response and reduced tumor growth. These results were inconsistent with earlier findings by Kim, et al. [24] , who proposed that IL-10 inhibition would promote the anti-tumor immune response. These contrary findings may be due to the intrinsically pleiotropic biological activity of IL-10 and the variability of cancer models [25] , or possibly genetic factors between different races. The exact function of IL-10 in glioma is not clear; further studies are required to elucidate the mechanisms underlying the association between IL-10 polymorphisms and glioma patient prognosis. This study was also the first to demonstrate that the PRKDC rs7003908 C/C genotype was correlated with poor prognosis in high-grade glioma patients. Rs7003908 was previously associated with increased risk of glioblastoma multiforme [14] , hepatocellular carcinoma [26] , prostate cancer [27] , and bladder cancer [28] . PRKDC encodes the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which is critical in the DNA damage response (DDR) and maintenance of genomic stability [29] . Goodwin, et al. [30] suggested that DNA-PKcs suppression inhibited tumor metastasis. Their group observed that DNA-PKcs induced cell migration, invasion, and metastasis, and was highly activated in advanced tumors, independent of DNA damage indicators. The same group [29] showed that PRKDC, as a transcriptional regulator, might promote tumor initiation and progression. Additionally, PRKDC expression and activity is increased in numerous tumor types, such as colorectal cancer [31] , esophageal cancer [10] , and B-cell chronic lymphocytic leukemias [11] . In the present study, we observed reduced OS and PFS in high-grade glioma patients carrying the PRKDC rs7003908 C/C genotype. This mutation may be associated with increased PRKDC expression, activity, or receptor activation, any of which might promote cell proliferation.
In conclusion, our data indicated that chemotherapy and extent of tumor resection were associated with improved glioma patient prognosis. IL-10 SNP rs1800871 was associated with improved survival in low-grade glioma cases, while PRKDC SNP rs7003908 was correlated with poor prognosis in high-grade patients. Although the exact mechanisms remain unclear, our results suggest that these two SNPs may be useful biomarkers for predicting glioma patient outcomes. Additionally, IL-10 and DNA-PKcs may be promising therapeutic targets for treatment of advanced malignancies. Further functional studies are needed to evaluate associations between rs1800871 and rs7003908 polymorphisms and glioma patient prognosis.
MATERIALS AND METHODS
Subjects
A total of 481 patients diagnosed with glioma at the Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Shaanxi Province (Xi'an, China) between September 2010 and April 2016 were randomly enrolled in this study. We used the following detailed selection criteria: recently diagnosed and histologically confirmed to have glioma (glioma was diagnosed via imaging and pathological analysis); Han Chinese patient with no kinship; underwent regular follow-up; peripheral blood samples available; no previous history of other cancers; and no prior treatment for glioma or prior treatment with chemotherapy or radiotherapy. Histopathological diagnosis was confirmed according to the World Health Organization (WHO) classification in 2007.
Our study protocol adhered to the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of Tangdu Hospital. All patients gave written informed consent prior to participation in the study.
DNA extraction and genotyping
Genomic DNA was extracted from glioma patient peripheral blood samples (5 mL) using GoldMagMini Whole Blood Genomic DNA Purification Kits 
Clinical data and follow-up
Patient treatment and survival (overall and progression-free) information was collected from a retrospective review of patient medical records or consultation with treating physicians. A standardized questionnaire was used to collect clinical data, including the date of diagnosis, follow-up date(s), patient age and gender, tumor histologic type, extent of resection, exact pathology, WHO grade, surgical methods, and postoperative radiotherapy and chemotherapy regimen(s). Follow-up consisted of outpatient visits, telephone interviews, and written communication with patients or their families. Clinical follow-up was performed in singleblind fashion with death as the end point. Glioma patients who were alive at the end of the follow-up period were excluded from the study. Data were stored electronically using the EpiData3.02 software, and validation, revision and conversion of assigned values were performed to establish the glioma patient database used for analysis. SPSS 17 .0 (SPSS, Chicago, IL, USA) was used to analyze follow-up and experimental data. Log-rank tests were used to compare survival curves. Univariate and multivariable Cox proportional hazard models were used to calculate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. Two-sided p-values < 0.05 were considered statistically significant and were calculated using the Wald test. HRs were adjusted for other factors that could affect glioma outcome, such as patient age and gender, and extent of tumor resection.
Statistical analyses
